R&D Trends

Koch Institute receives $1M from Takeda to support immuno-oncology research

Friday, February 10, 2017

Takeda Pharmaceutical and the Koch Institute for Integrative Cancer Research at MIT jointly announced that Takeda will support groundbreaking science in immuno-oncology at the Koch Institute. Over the next two years, the $1 million gift will help to build upon the research currently being conducted by the Institute to investigate the role of the immune response in cancer and develop potential novel treatments.

[Read More]

NIH to expand critical catalog for genomics research

Monday, February 6, 2017

The NIH plans to expand its Encyclopedia of DNA Elements (ENCODE) Project, a genomics resource used by many scientists to study human health and disease. Funded by the National Human Genome Research Institute (NHGRI), part of NIH, the ENCODE Project is generating a catalog of all the genes and regulatory elements—the parts of the genome that control whether genes are active or not—in humans and select model organisms. With four years of additional support, NHGRI builds on a long-standing commitment to developing freely available genomics resources for use by the scientific community.

[Read More]

All of Us Research Program announces funding opportunity for community partners

Thursday, February 2, 2017

The NIH has announced a new opportunity for organizations interested in helping engage volunteers in the All of Us Research Program, part of the Precision Medicine Initiative. This funding opportunity, open to national and regional organizations, as well as local community groups, will support activities to promote enrollment and retention in the All of Us Research Program across diverse communities.

[Read More]

ESSA Pharma receives $4M from Research Institute of Texas

Wednesday, February 1, 2017

ESSA Pharma, a pharmaceutical company, currently in the clinical development stage, focused on the development of small molecule drugs for the treatment of prostate cancer, announced the receipt of a $4 million payment from the Cancer Prevention Research Institute of Texas (CPRIT). The payment is part of a total non-dilutive grant of $12 million, repayable out of potential product revenues, which was originally awarded in February 29, 2014.

[Read More]

Neuropore Therapies awarded Parkinson’s research grant from Michael J. Fox Foundation

Tuesday, January 31, 2017

Neuropore Therapies, a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

[Read More]

Christiana Care Health System’s Gene Editing Institute awarded genomic cancer research grant from BIRD Foundation

Tuesday, January 31, 2017

For its enormous potential to accelerate the development of personalized cancer therapies, the Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute has been awarded a grant of $900,000 from the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation in partnership with the biotechnology company NovellusDx.

[Read More]

Lundbeck, IBM Watson Health collaborate on neurological disorders

Monday, January 30, 2017

Lundbeck is collaborating with IBM‘s Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck’s expertise in the treatment of psychiatric and neurological disorders with IBM’s cognitive and knowledge-based analytics to foster the discovery and development of new innovative treatments of disorders such as schizophrenia and Parkinson’s disease.

[Read More]

J&J to acquire Actelion for $30B, spin-out new R&D company

Friday, January 27, 2017

Johnson & Johnson and Actelion have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, which equates to CHF 280.08 per share as of January 25, 2017. The transaction, which was unanimously approved by the boards of directors of both companies, is expected to be immediately accretive to Johnson & Johnson adjusted earnings per share and accelerate Johnson & Johnson revenue and earnings growth rates. Johnson & Johnson will fund the transaction with cash held outside the U.S.

[Read More]